A Wallerian degeneration pattern in patients at risk for MS

Neurology

Volumn 54, Issue 5, 2000, Pages 1155-1160

  Simon, J H ^a   Kinkel, R P ^b   Jacobs, L ^d   Bub, L ^a   Simonian, N ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BIOGEN   (United States)

^d Neuroradiology/MRI ^*

Author keywords

MS; Wallerian degeneration

Indexed keywords

BETA1A INTERFERON; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PYRAMIDAL TRACT; RANDOMIZED CONTROLLED TRIAL;

EID: 0034646386     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.5.1155     Document Type: Article

References (38)

1. Allen IV. Demyelinating diseases. In: Adams JH, Corsellis JAN, Duchen LW, eds. Greenfield's neuropathology. 4th ed. New York: John Wiley & Sons, 1984:338-384.
2. Lumsden CE. The neuropathology of Multiple sclerosis. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. North Holland, Amsterdam: Elsevier Science Publishers 1970;9:217-309.
3. Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion. A quantitative MRI and electron microscopy study. Brain 1991;114:1271-1280.
4. McDonald WI. Rachelle Fishman-Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol 1994;53:338-343.
5. Waxman SG. Demyelinating diseases - new pathological insights, new therapeutic targets. N Engl J Med 1998;338:323-325.
6. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transsection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
8. Arnold DL, Wolinsky JS, Matthews PM, Falini A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:S94-S101.
9. Waller AV. Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of the primitive fiber. Philos Trans R Soc Lond [Biol] 1850;140:423-429.
10. Adams RD, Kubik CS. Morbid anatomy of the demyelinative diseases. Am J Med 1952; 12:510-546.
11. Weller RO. Pathology of multiple sclerosis. In: Matthews WB, Acheson ED, Batchelor JR, Weller RO, eds. McAlpine's multiple sclerosis. London: Churchill Livingstone, 1985:301-343.
12. Griffin JW, George R, Lobato C, Tyor WR, Yan LC, Glass JD. Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination. J Neuroimmunol 1992;40:153-165.
13. Inoue Y, Matsumura Y, Fukuda T, et al. MR imaging of Wallerian degeneration in the brainstem: temporal relationships. AJNR Am J Neuroradiol 1990;11:897-902.
14. Orita T, Tsurutani T, Izumihara A, Kajiwara K. Early, evolving Wallerian degeneration of the pyramidal tract in cerebrovascular diseases: MR study. J Comput Assist Tomogr 1994; 18:943-946.
15. Kuhn MJ, Mikulis DJ, Ayoub DM, Kosofsky BE, Davis KR, Taveras JM. Wallerian degeneration after cerebral infarction: evaluation with sequential MR imaging. Radiology 1989; 172: 179-182.
16. Jacobs LD, Beck RW, Brownscheidle CM, et al. A profile of patients at high risk for the development of clinically definite MS (CDMS): the first report of the CHAMPS study. Neurology 1999;52:A495. Abstract.
17. Jacobs L, Kinkel PR, Kinkel WR. Silent brain lesions in patients with isolated idiopathic optic neuritis. Arch Neurol 1986;43:452-455.
18. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503.
19. Morissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic reonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Five-year follow-up study. Brain 1993;116:135-146.
20. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: Experience of the optic neuritis treatment trial. Neurology 1997;49:1404-1413.
21. Miyai I, Suzuki T, Kii K, et al. Wallerian degeneration of the pyramidal tract does not affect stroke rehabilitation outcome. Neurology 1998;51:1613-1616.
22. Waragai M, Watanabe H, Iwabuchi S. The somatotopic localization of the descending cortical tract in the cerebral peduncle: a study using MRI of changes following Wallerian degeneration in the cerebral peduncle after a supratentorial vascular lesion. Neuroradiol 1994;36:402-404.
23. Simon JH. The use of magnetic resonance imaging to select patients for multiple sclerosis clinical trials. In: Filippi M, Grossman RI, Comi G, eds. Magnetic resonance techniques in clinical trials in multiple sclerosis. Milan, Italy: Springer-Verlag, 1999:21-36.
24. Tas MW, Barkhof F, van Walderveen MA, Polman CH, Hommes OR, Valk J. The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol 1995;16:259-264.
25. Sawlani V, Gupta RK, Singh MK, Kohli A. MRI demonstration of Wallerian degeneration in various intracranial lesions and its clinical implications. J Neurol Sci 1997;146:103-108.
26. Goodkin DS, Rowley HA, Olney RK. Magnetic resonance imaging in amyotrophic lateral sclerosis. Ann Neurol 1988;23: 418-420.
27. Cobb SR, Mehringer CM. Wallerian degeneration in a patient with Schilder disease: MR imaging demonstration. Radiology 1987;162:521-522.
28. Stoll G, Griffin JW, Li CY, Trapp BD. Wallerian degeneration in the peripheral nervous system: participation of both Schwann cells and macrophages in myelin degradation. J Neurocytol 1989;18:671-683.
29. Stoll G, Trapp BD, Griffin JW. Macrophage function during Wallerian degeneration of rat optic nerve: clearance of degenerating myelin and Ia expression. J Neurosci 1989;9:2327-2335.
30. Lexa FJ, Grossman RI, Rosenquist AC. Dyke Award Paper. MR of Wallerian degeneration in the feline visual system: characterization by magnetization transfer rate with histopathologic correlation. AJNR Am J Neuroradiol 1994;15: 201-212.
31. Grossman RI, Hecht-Leavitt CM, Evans SM, et al. Experimental radiation injury: combined MR imaging and spectroscopy. Radiology 1988;169:305-309.
32. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632-2637.
33. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-1592.
34. Naryanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385-391.
35. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103-113.
36. Simon JH, Jacobs D, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999;53:139-148.
37. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
38. Miller DE, Simon JH, Rudick RA, Jacobs LD. Determinants of brain atrophy in relapsing Multiple Sclerosis. Neurology 1999; 52:A357. Abstract.